血管性认知障碍血浆生物标志物的研究进展
Advances in Plasma Biomarkers of Vascular Cognitive Impairment
DOI: 10.12677/acm.2024.1492448, PDF,    科研立项经费支持
作者: 王建行, 陈泠羽, 陈肖杰：牡丹江医科大学研究生院，黑龙江 牡丹江；张春玲：阿勒泰地区妇幼保健院，新疆 阿勒泰；赵维纳*：牡丹江医科大学附属红旗医院神经内科，黑龙江 牡丹江；黑龙江省缺血性脑卒中防治重点实验室，黑龙江 牡丹江
关键词: 血管性认知障碍；血浆生物标志物；血管性痴呆；Vascular Cognitive Impairment； Plasma Biomarker； Vascular Dementia
摘要: 血管性认知障碍(VCI)主要由血管危险因素和脑血管疾病引起。VCI包括广泛的认知障碍，从轻度认知障碍到缺血性或出血性卒中引起的血管性痴呆，也包含合并阿尔茨海默病等混合性病理所致的不同程度的认知障碍。目前针对VCI的药物治疗研究多集中在VaD (重度VCI)，且这些效果并未带来日常生活能力的明显改善。寻找新的生物标志物是对VCI进行诊断和治疗的关键一步。近年来，以血液为标本筛选合适的VCI生物标志物研究得到了广泛开展。本文旨在对血浆中血管性认知障碍生物标志物的研究现状进行综述，以寻找适合VCI患者诊断的生物学工具。
Abstract: Vascular cognitive impairment (VCI) is mainly caused by vascular risk factors and cerebrovascular disease. VCI includes a wide range of cognitive impairments, from mild cognitive impairment to vascular dementia due to ischemic or hemorrhagic stroke, as well as varying degrees of cognitive deficits due to comorbid pathologies such as Alzheimer’s disease. Current pharmacotherapy studies for VCI have focused on VaD (severe VCI), and these effects have not led to significant improvements in the ability to perform activities of daily living. The search for new biomarkers is a crucial step in the diagnosis and treatment of VCI. In recent years, blood-based specimen screening studies for suitable biomarkers of VCI have been widely conducted. The aim of this paper is to review the current status of research on biomarkers of vascular cognitive impairment in plasma in order to find suitable biological tools for the diagnosis of patients with VCI.
文章引用：王建行, 陈泠羽, 陈肖杰, 张春玲, 赵维纳. 血管性认知障碍血浆生物标志物的研究进展[J]. 临床医学进展, 2024, 14(9): 200-208. https://doi.org/10.12677/acm.2024.1492448

参考文献

[1] Schoeni, R.F., Freedman, V.A. and Langa, K.M. (2018) Introduction to a Supplement on Population Level Trends in Dementia: Causes, Disparities, and Projections. The Journals of Gerontology: Series B, 73, S1-S9. [Google Scholar] [CrossRef] [PubMed]
[2] Bir, S.C., Khan, M.W., Javalkar, V., Toledo, E.G. and Kelley, R.E. (2021) Emerging Concepts in Vascular Dementia: A Review. Journal of Stroke and Cerebrovascular Diseases, 30, Article ID: 105864. [Google Scholar] [CrossRef] [PubMed]
[3] Corriveau, R.A., Bosetti, F., Emr, M., Gladman, J.T., Koenig, J.I., Moy, C.S., et al. (2016) The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline. Cellular and Molecular Neurobiology, 36, 281-288. [Google Scholar] [CrossRef] [PubMed]
[4] Rundek, T., Tolea, M., Ariko, T., Fagerli, E.A. and Camargo, C.J. (2022) Vascular Cognitive Impairment (VCI). Neurotherapeutics, 19, 68-88. [Google Scholar] [CrossRef] [PubMed]
[5] Wilcock, D., Jicha, G., Blacker, D., Albert, M.S., D’Orazio, L.M., Elahi, F.M., et al. (2021) MarkVCID Cerebral Small Vessel Consortium: I. Enrollment, Clinical, Fluid Protocols. Alzheimer’s & Dementia, 17, 704-715. [Google Scholar] [CrossRef] [PubMed]
[6] Saliminejad, K., Khorram Khorshid, H.R., Soleymani Fard, S. and Ghaffari, S.H. (2018) An Overview of MicroRNAs: Biology, Functions, Therapeutics, and Analysis Methods. Journal of Cellular Physiology, 234, 5451-5465. [Google Scholar] [CrossRef] [PubMed]
[7] Yuan, M. and Bi, X. (2020) Therapeutic and Diagnostic Potential of MicroRNAs in Vascular Cognitive Impairment. Journal of Molecular Neuroscience, 70, 1619-1628. [Google Scholar] [CrossRef] [PubMed]
[8] Prabhakar, P., Chandra, S.R. and Christopher, R. (2017) Circulating MicroRNAs as Potential Biomarkers for the Identification of Vascular Dementia Due to Cerebral Small Vessel Disease. Age and Ageing, 46, 861-864. [Google Scholar] [CrossRef] [PubMed]
[9] Ansari, A., Maffioletti, E., Milanesi, E., Marizzoni, M., Frisoni, G.B., Blin, O., et al. (2019) miR-146a and miR-181a Are Involved in the Progression of Mild Cognitive Impairment to Alzheimer’s Disease. Neurobiology of Aging, 82, 102-109. [Google Scholar] [CrossRef] [PubMed]
[10] Toyama, K., Spin, J.M., Tsao, P.S., Maruyama, K., Osawa, H., Mogi, M., et al. (2023) Serum microRNA‐501‐3p Is a Potential Diagnostic Tool for Detecting Mild Cognitive Impairment: Ehime Genome Study. Journal of Neurochemistry, 166, 960-971. [Google Scholar] [CrossRef] [PubMed]
[11] Zhao, W., Sun, W., Li, S., Jiao, Y., Wang, Z., Wu, T., et al. (2021) Exosomal MiRNA-223-3p as Potential Biomarkers in Patients with Cerebral Small Vessel Disease Cognitive Impairment. Annals of Translational Medicine, 9, 1781-1781. [Google Scholar] [CrossRef] [PubMed]
[12] Niu, Y., Wan, C., Zhang, J., Zhang, S., Zhao, Z., Zhu, L., et al. (2021) Aerobic Exercise Improves VCI through circRIMS2/miR-186/BDNF-Mediated Neuronal Apoptosis. Molecular Medicine, 27, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[13] Yan, M., Zhang, S., Zhao, H., Xia, S., Jin, Z., Xu, Y., et al. (2020) MicroRNA-153 Impairs Presynaptic Plasticity by Blocking Vesicle Release Following Chronic Brain Hypoperfusion. Cell Communication and Signaling, 18, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
[14] Zheng, W., Zhang, J., Zhou, B. and Chang, H. (2022) miR-322-5p Alleviates Cell Injury and Impairment of Cognitive Function in Vascular Dementia by Targeting TSPAN5. Yonsei Medical Journal, 63, 282-291. [Google Scholar] [CrossRef] [PubMed]
[15] Yu, K.Q., Xu, R., Wu, L.X., et al. (2023) Effects of MicroRNA-320 on Learning and Memory in Mice with Vascular Cognitive Impairment Caused via Cerebral Ischemia. Cellular and Molecular Biology, 69, 112-119. [Google Scholar] [CrossRef] [PubMed]
[16] Sha, S., Tan, J., Miao, Y. and Zhang, Q. (2021) The Role of Autophagy in Hypoxia-Induced Neuroinflammation. DNA and Cell Biology, 40, 733-739. [Google Scholar] [CrossRef] [PubMed]
[17] Poh, L., Sim, W.L., Jo, D., Dinh, Q.N., Drummond, G.R., Sobey, C.G., et al. (2022) The Role of Inflammasomes in Vascular Cognitive Impairment. Molecular Neurodegeneration, 17, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[18] Tian, Z., Ji, X. and Liu, J. (2022) Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects. International Journal of Molecular Sciences, 23, Article No. 6224. [Google Scholar] [CrossRef] [PubMed]
[19] Rajeev, V., Chai, Y.L., Poh, L., Selvaraji, S., Fann, D.Y., Jo, D., et al. (2023) Chronic Cerebral Hypoperfusion: A Critical Feature in Unravelling the Etiology of Vascular Cognitive Impairment. Acta Neuropathologica Communications, 11, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[20] Jagtap, A., Gawande, S. and Sharma, S. (2015) Biomarkers in Vascular Dementia: A Recent Update. Biomarkers and Genomic Medicine, 7, 43-56. [Google Scholar] [CrossRef] 
[21] Walker, K.A., Gottesman, R.F., Wu, A., Knopman, D.S., Gross, A.L., Mosley, T.H., et al. (2019) Systemic Inflammation during Midlife and Cognitive Change over 20 Years: The ARIC Study. Neurology, 92, e1256-e1267. [Google Scholar] [CrossRef] [PubMed]
[22] Long, S., Chen, Y., Meng, Y., Yang, Z., Wei, M., Li, T., et al. (2023) Peripheral High Levels of CRP Predict Progression from Normal Cognition to Dementia: A Systematic Review and Meta-Analysis. Journal of Clinical Neuroscience, 107, 54-63. [Google Scholar] [CrossRef] [PubMed]
[23] Liu, P., Liu, X., Chen, J., Zhang, Y., Chen, J., Yu, L., et al. (2024) Butylphthalide Combined with Donepezil for the Treatment of Vascular Dementia: A Meta-Analysis. Journal of International Medical Research, 52. [Google Scholar] [CrossRef] [PubMed]
[24] Custodero, C., Ciavarella, A., Panza, F., Gnocchi, D., Lenato, G.M., Lee, J., et al. (2022) Role of Inflammatory Markers in the Diagnosis of Vascular Contributions to Cognitive Impairment and Dementia: A Systematic Review and Meta-analysis. GeroScience, 44, 1373-1392. [Google Scholar] [CrossRef] [PubMed]
[25] Anita, N.Z., Zebarth, J., Chan, B., Wu, C., Syed, T., Shahrul, D., et al. (2022) Inflammatory Markers in Type 2 Diabetes with vs. without Cognitive Impairment; a Systematic Review and Meta-Analysis. Brain, Behavior, and Immunity, 100, 55-69. [Google Scholar] [CrossRef] [PubMed]
[26] Hanson, J.E., Yuan, H., Perszyk, R.E., Banke, T.G., Xing, H., Tsai, M., et al. (2023) Therapeutic Potential of N-Methyl-D-Aspartate Receptor Modulators in Psychiatry. Neuropsychopharmacology, 49, 51-66. [Google Scholar] [CrossRef] [PubMed]
[27] Busse, M., Kunschmann, R., Dobrowolny, H., Hoffmann, J., Bogerts, B., Steiner, J., et al. (2017) Dysfunction of the Blood-Cerebrospinal Fluid-Barrier and N-Methyl-D-Aspartate Glutamate Receptor Antibodies in Dementias. European Archives of Psychiatry and Clinical Neuroscience, 268, 483-492. [Google Scholar] [CrossRef] [PubMed]
[28] Dobrynina, L.A., Alexandrova, E.V., Zabitova, M.R., Kalashnikova, L.A., Krotenkova, M.V. and Akhmetzyanov, B.M. (2021) Anti-NR2 Glutamate Receptor Antibodies as an Early Biomarker of Cerebral Small Vessel Disease. Clinical Biochemistry, 96, 26-32. [Google Scholar] [CrossRef] [PubMed]
[29] Langeh, U. (2021) Targeting S100B Protein as a Surrogate Biomarker and Its Role in Various Neurological Disorders. Current Neuropharmacology, 19, 265-277. [Google Scholar] [CrossRef] 
[30] Wang, F., Zou, Z., Yuan, D., Gong, Y., Zhang, L., Chen, X., et al. (2017) Correlation between Serum S100β Protein Levels and Cognitive Dysfunction in Patients with Cerebral Small Vessel Disease: A Case-Control Study. Bioscience Reports, 37, BSR20160446. [Google Scholar] [CrossRef] [PubMed]
[31] Petersen, M.A., Ryu, J.K. and Akassoglou, K. (2018) Fibrinogen in Neurological Diseases: Mechanisms, Imaging and Therapeutics. Nature Reviews Neuroscience, 19, 283-301. [Google Scholar] [CrossRef] [PubMed]
[32] Pyun, J., Ryoo, N., Park, Y.H. and Kim, S. (2020) Fibrinogen Levels and Cognitive Profile Differences in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 49, 489-496. [Google Scholar] [CrossRef] [PubMed]
[33] Gillett, S.R., McClure, L.A., Callas, P.W., Thacker, E.L., Unverzagt, F.W., Wadley, V.G., et al. (2018) Hemostasis Biomarkers and Incident Cognitive Impairment: The REGARDS Study. Journal of Thrombosis and Haemostasis, 16, 1259-1267. [Google Scholar] [CrossRef] [PubMed]
[34] Loures, C.d.M.G., Duarte, R.C.F., Silva, M.V.F., Cicarini, W.B., de Souza, L.C., Caramelli, P., et al. (2019) Hemostatic Abnormalities in Dementia: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 45, 514-522. [Google Scholar] [CrossRef] [PubMed]
[35] Huang, F., Wang, K. and Shen, J. (2019) Lipoprotein‐Associated Phospholipase A2: The Story Continues. Medicinal Research Reviews, 40, 79-134. [Google Scholar] [CrossRef] [PubMed]
[36] Zhang, Q.L., Lu, P. and Zhang, J.W. (2018) Association of Serum Lipoprotein-Associated Phospholipase A2 with Vascular Dementia after Ischemic Stroke. Chinese Medical Journal, 98, 1171-1175.
[37] Zuliani, G., Marsillach, J., Trentini, A., Rosta, V. and Cervellati, C. (2023) Lipoprotein-Associated Phospholipase A2 Activity as Potential Biomarker of Vascular Dementia. Antioxidants, 12, Article No. 597. [Google Scholar] [CrossRef] [PubMed]
[38] Zhu, S., Wei, X., Yang, X., Huang, Z., Chang, Z., Xie, F., et al. (2019) Plasma Lipoprotein-Associated Phospholipase A2 and Superoxide Dismutase Are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment. Aging and Disease, 10, 834-846. [Google Scholar] [CrossRef] [PubMed]
[39] Smith, A.D. and Refsum, H. (2021) Homocysteine—From Disease Biomarker to Disease Prevention. Journal of Internal Medicine, 290, 826-854. [Google Scholar] [CrossRef] [PubMed]
[40] Smith, A.D. and Refsum, H. (2016) Homocysteine, B Vitamins, and Cognitive Impairment. Annual Review of Nutrition, 36, 211-239. [Google Scholar] [CrossRef] [PubMed]
[41] Wang, T., Sun, Z., Shao, L., Xu, X., Liu, Y., Qin, M., et al. (2017) Diagnostic Values of Serum Levels of Homocysteine and Uric Acid for Predicting Vascular Mild Cognitive Impairment in Patients with Cerebral Small Vessel Disease. Medical Science Monitor, 23, 2217-2225. [Google Scholar] [CrossRef] [PubMed]
[42] Cao, L. and Sun, Z. (2022) Diagnostic Values of Serum Levels of Homocysteine, Heat Shock Protein 70 and High-Sensitivity C-Reactive Protein for Predicting Vascular Cognitive Impairment. Neuropsychiatric Disease and Treatment, 18, 525-533. [Google Scholar] [CrossRef] [PubMed]
[43] Wang, X., Qiao, T., Liu, M. and Wang, X. (2021) Homocysteine Associated with Low Cognitive Function Independent of Asymptomatic Intracranial and Carotid Arteries Stenoses in Chinese Elderly Patients: An Outpatient-Based Cross-Sectional Study. Journal of Geriatric Psychiatry and Neurology, 35, 302-308. [Google Scholar] [CrossRef] [PubMed]
[44] Ji, Y., Li, X., Teng, Z., Li, X., Jin, W. and Lv, P.y. (2020) Homocysteine Is Associated with the Development of Cerebral Small Vessel Disease: Retrospective Analyses from Neuroimaging and Cognitive Outcomes. Journal of Stroke and Cerebrovascular Diseases, 29, Article ID: 105393. [Google Scholar] [CrossRef] [PubMed]
[45] Moretti, R., Caruso, P., Dal Ben, M., Conti, C., Gazzin, S. and Tiribelli, C. (2017) Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia. Frontiers in Aging Neuroscience, 9, Article No. 169. [Google Scholar] [CrossRef] [PubMed]
[46] Hosoki, S., Hansra, G.K., Jayasena, T., Poljak, A., Mather, K.A., Catts, V.S., et al. (2023) Molecular Biomarkers for Vascular Cognitive Impairment and Dementia. Nature Reviews Neurology, 19, 737-753. [Google Scholar] [CrossRef] [PubMed]
[47] Aronson, J.K. and Ferner, R.E. (2017) Biomarkers—A General Review. Current Protocols in Pharmacology, 76, 9.23.1-9.23.17. [Google Scholar] [CrossRef] [PubMed]

为你推荐